SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is experiencing significant volatility as investors weigh the company's aggressive investments in AI infrastructure against concerns over its debt load and recent workforce reductions. While the community remains divided, many retail participants are actively discussing whether this pullback represents a deep-value opportunity or a structural decline, with significant debate occurring over the stock's long-term potential versus immediate selling pressure.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy Corp

Bloom Energy is currently a focal point for investors due to its critical role in providing rapid, decentralized power solutions for AI data centers amid a broader sector trend of power infrastructure bottlenecks. Market participants are actively debating the stock's high volatility and valuation, with community sentiment split between bullish enthusiasm for its long-term growth potential and caution regarding potential overextension and sensitivity to broader macroeconomic pressures.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is seeing intense momentum as the community reacts to its upcoming inclusion in the Nasdaq-100 index, with many traders closely monitoring a potential short squeeze and high-volume institutional buying. Investors are fiercely debating whether the stock's parabolic ascentfueled by critical AI hardware demandis a sustainable re-rating or a classic blow-off top.

Maulcoin

Maulcoin is surging as a highly engaged community rallies behind a 'no-rug' narrative, pushing for aggressive growth milestones and a potential breakout. Investors are actively discussing the coin's rapid momentum, calling for sustained 'diamond hand' holding, and coordinating social media challenges to drive new awareness.

Avis Budget Group, Inc. engages in the provision of vehicle sharing and rental services. It operates through the Americas and International segments. The Americas segment includes vehicle rental and car sharing operations in North America, South America, Central America, and the Caribbean. The International segment is involved in vehicle rental and car sharing operations in Europe, the Middle East, Africa, Asia, and Australasia. The company was founded in 1946 and is headquartered in Parsippany, NJ.

Avis Budget Group Inc

Avis Budget Group is experiencing a massive, volatile short squeeze that has drawn comparisons to previous meme-stock phenomena, leaving the community sharply divided between those riding the parabolic momentum and those betting on an inevitable, fundamental-driven collapse. Investors are closely monitoring record-high short interest and limited share availability, which continue to fuel extreme price swings and intense debate over potential share dilution or regulatory intervention.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave Inc. is experiencing intense market interest driven by back-to-back major partnerships with Meta and Anthropic, which have significantly bolstered the company's AI infrastructure narrative. While community sentiment remains polarized between bullish investors cheering the massive contract expansion and skeptics raising concerns over high debt loads and frequent capital raises, the stock is seeing significant institutional options flow and volatility as traders debate whether these deals mark a structural shift in AI cloud competition.

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.

Travere Therapeutics Inc

Travere Therapeutics is experiencing a significant surge in investor attention following the FDA's decision to grant full approval for FILSPARI in IgA nephropathy, marking a major milestone for the company. The community is actively debating the stock's future, with many weighing the positive momentum of this regulatory win against potential volatility and long-term valuation concerns.

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo Technology is surging following an announcement that it will acquire DustPhotonics for $750 million to bolster its AI-driven silicon photonics capabilities. The community is actively discussing this strategic expansion as a major growth catalyst, with investors debating the company's valuation and its potential to capture significant market share in the rapidly evolving data center connectivity sector.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as investors react to speculation surrounding potential leadership changes at the FDA's CBER, which could shift the regulatory environment for its lead drug candidate, Deramiocel. The community is actively discussing the possibility of early approval and the potential for a significant valuation re-rating, viewing recent stock volatility as institutional positioning ahead of a major catalyst.

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

Revolution Medicines is trending following the FDA's decision to award daraxonrasib a National Priority Voucher, a milestone that highlights the stock's pivotal position in treating pancreatic cancer. The community is actively discussing the stock's significant breakthrough potential, with many investors debating its long-term valuation compared to competitors and the likelihood of its emergence as a major M&A target in the oncology sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Listed Funds Trust - Wahed FTSE USA Shariah ETF

Start of a real move higher

Dead cat - we retest the lows

Show me the results

Software is bouncing hard today. Is this the start of a sustained recovery or just a dead cat bounce before we retest the lows?

Current Price	$62.73
Prev Close	$62.12
Open	$62.02
Dividend Yield	N/A
50-Day Moving Average	$61.67
Beta	N/A
Avg. Volume	61,932.73
PE Ratio	N/A

52-Week High	$64.19
52-Week Low	$44.07
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

HLAL
Listed Funds Trust - Wahed FTSE USA Shariah ETF

Feed

News

Sentiment

Fundamentals

Info

Latest HLAL News

HLALListed Funds Trust - Wahed FTSE USA Shariah ETF